Long-Term Monitoring of AEs and Reintegrating Patients back into Community Care
The discussion focuses on protocols for monitoring long-term complications from CAR T-cell and bispecific therapies, improving patient reintegration into community care posttreatment, and enhancing communication between academic and community oncologists.
Video content above is prompted by the following:
- What protocols and processes do you have in place to continue monitoring and managing potential long-term complications or adverse events associated with CAR T-cell and bispecific therapy (risk of infections, etc)?
- How can we improve the reintegration of patients into community care after receiving treatment at an academic center?
- How can we improve communication between academic and community oncologists throughout the referral and treatment process?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
